The promise and potential of stem cell research is apparent. However, ethical questions still linger. There is as yet no consensus in the U.S. Congress on how to address the issue of reproductive cloning and media confusion of this and the quite separate issue of therapeutic cloning inhibits therapeutic advance. This paper outlines the need for the FDA to undertake a deliberate process, with input from all stakeholders, to authoritatively establish its jurisdiction over human reproductive cloning so as to foster the life-saving potential of therapeutic cloning.
Get full access to this article
View all access options for this article.
References
1.
TachibanaMet al. (2013). Human embryonic stem cells derived by somatic cell nuclear transfer. Cell, 153:1228–1238.
2.
MerrillRA. (2002). Human tissues and reproductive cloning: new technologies challenge FDA. Houst J Health Law Policy, 3:1–82.
3.
MerrillRA and RoseBJ. (2001). FDA regulation of human cloning: usurpation or statesmanship?. Harv J Law Technol, 15:85–148.
4.
GueninLM. (2005). Stem cells, cloning, and regulation. Mayo Clin Proc, 80:241–250.
5.
California Institute for Regenerative Medicine. Oregon research team derives embryonic stem cells via nuclear transfer. June2013. Newsletter. www.cirm.ca.gov/about-cirm/newsletter/june-2013-newsletter#scnt
6.
California Institute for Regenerative Medicine Blog Post. Caffeine held the key to creating embryonic stem cells from cloned embryos. May15, 2013. http://cirmresearch.blogspot.com/2013/05/caffeine-held-key-to-creating-embryonic.html
7.
For Clonaid, a trail of unproven claims. N.Y. Times, January1, 2003. www.nytimes.com/2003/01/01/us/for-clonaid-a-trail-of-unproven-claims.html
8.
U.S. Food and Drug Administration. Cloning. Vaccines, Blood & Biologics. www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/Cloning/default.htm
